Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutant myogenin promoter-controlled oncolytic adenovirus selectively kills PAX3-FOXO1-positive rhabdomyosarcoma cells

17 Dec 2020

Abstract excerpt

The PAX3-FOXO1 fusion gene functions as a transactivator and increases expression of many cancer-related genes. These lead to metastases and other unfavorable outcomes for alveolar rhabdomyosarcoma (ARMS) patients. In order to target ARMS with the PAX3-FOXO1 transactivator, we developed an Oncolytic Adenovirus (OAd) regulated by the myogenin (pMYOG) promoter with a mutation in the Myocyte Enhancer Factor-2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Sarcoma Diagnosis and Treatment
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33338875
DOI: 10.1016/j.tranon.2020.100997

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutant myogenin promoter-controlled oncolytic adenovirus selectively kills PAX3-FOXO1-positive rhabdomyosarcoma cellsPMID 33338875Read ↗

Therapeutic Approaches Targeting PAX3-FOXO1 and Its Regulatory and Transcriptional Pathways in RhabdomyosarcomaSemantic proximity Read ↗

PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcomaSemantic proximity Read ↗

Molecular diagnostics in the management of rhabdomyosarcomaSemantic proximity Read ↗

Genomic and Epigenetic Changes Drive Aberrant Skeletal Muscle Differentiation in RhabdomyosarcomaSemantic proximity Read ↗

PAX3–FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcomaSemantic proximity Read ↗

RUNX2 inhibition disrupts a PAX3::FOXO1-RUNX2 feed-forward loop and dismantles oncogenic gene programs in fusion-positive rhabdomyosarcomaSemantic proximity Read ↗

Novel Synthetic Promoter Armed Oncolytic Herpes Simplex Virus For Treatment of PAX3-FOXO1 Positive RhabdomyosarcomaSemantic proximity Read ↗

Transforming Growth Factor Beta and Alveolar Rhabdomyosarcoma: A Challenge of Tumor Differentiation and Chemotherapy ResponseSemantic proximity Read ↗

Defining the Cooperative Genetic Changes That Temporally Drive Alveolar RhabdomyosarcomaSemantic proximity Read ↗

A call to ARMS: targeting the<i>PAX3-FOXO1</i>gene in alveolar rhabdomyosarcomaSemantic proximity Read ↗

KDM3A/Ets1 epigenetic axis contributes to PAX3/FOXO1-driven and independent disease-promoting gene expression in fusion-positive Rhabdomyosarcoma.Semantic proximity Read ↗

Fusion transcriptome profiling provides insights into alveolar rhabdomyosarcomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.